<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869440</url>
  </required_header>
  <id_info>
    <org_study_id>CNS 7056-003</org_study_id>
    <nct_id>NCT00869440</nct_id>
  </id_info>
  <brief_title>Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy</brief_title>
  <official_title>A Phase IIa, Randomized, Controlled, Double-Blind, Dose-Finding Study Evaluating the Safety and Pharmacodynamics of CNS 7056 in Patients Undergoing Diagnostic Upper GI Endoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paion UK Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Paion UK Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the safety and efficacy of CNS 7056 as a procedural
      sedative at three dose levels compared to midazolam during a diagnostic upper GI endoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, double-blind, parallel-group, dose-finding study assessing the safety
      and efficacy of three dose levels of CNS 7056 compared with midazolam in patients undergoing
      diagnostic upper GI endoscopy.

      Patients who met all study entry criteria and completed screening procedures were randomly
      assigned to 1 of 4 treatment groups: CNS 7056 0.10 mg/kg,0.15 mg/kg, or 0.20 mg/kg; or
      midazolam 0.075 mg/kg. Patients received their assigned treatment administered as a single
      intravenous injection by a syringe driver over 1 minute. The endoscopy started when a
      Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score of ≤3 has been reached,
      but no earlier than 90 seconds after Time 0 (the start of study drug injection). Rescue with
      sedative medication (midazolam 1-2 mg) was be permitted at the discretion of the
      administering physician.

      Efficacy assessments consisted of the MOAA/S scores, Aldrete scores, and drowsiness measures
      using a Visual Analogue Scale (VAS). Cognitive function was assessed by the Hopkins Verbal
      Learning Test-Revised™ (HVLT-R™) and memory for the procedure by the Brice Questionnaire.

      Safety assessments included adverse events, physical examinations, vital signs, ECGs, pulse
      oximetry measurements, clinical laboratory tests, and pain on injection using a VAS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success Rates of the Procedure</measure>
    <time_frame>From start of study drug injection to patient discharge</time_frame>
    <description>Success of the procedure is a composite endpoint consisting of: MOAA/S scores ≤4 on three consecutive measurements after administration of study drug AND completion of the endoscopy procedure AND no requirement for rescue sedative medication AND no requirement for manual or mechanical ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Fully Alert</measure>
    <time_frame>From study drug administration until fully alert criteria are reached</time_frame>
    <description>Time to first of 3 consecutive Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scores of 5 following study drug administration in patients who underwent the endoscopy procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Ready for Discharge</measure>
    <time_frame>From the end of the endoscopy procedure up to 120 minutes or until 3 consecutive Aldrete scores of ≥9 are reached, whichever occurs first</time_frame>
    <description>Time to first of 3 consecutive Aldrete scores ≥9 after the end endoscopy procedure</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Procedural Sedation</condition>
  <condition>Endoscopy</condition>
  <arm_group>
    <arm_group_label>1: Remimazolam (CNS 7056) 0.10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remimazolam (CNS 7056) 0.10 mg/kg iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Remimazolam (CNS 7056) 0.15 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remimazolam (CNS 7056) 0.15 mg/kg iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Remimazolam (CNS 7056) 0.20 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remimazolam (CNS 7056) 0.20 mg/kg iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4: Midazolam 0.075 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Midazolam 0.075 mg/kg iv</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNS 7056</intervention_name>
    <description>Administered as a single intravenous injection by a syringe driver over 1 minute</description>
    <arm_group_label>1: Remimazolam (CNS 7056) 0.10 mg/kg</arm_group_label>
    <arm_group_label>2: Remimazolam (CNS 7056) 0.15 mg/kg</arm_group_label>
    <arm_group_label>3: Remimazolam (CNS 7056) 0.20 mg/kg</arm_group_label>
    <other_name>remimazolam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Administered as a single intravenous injection by a syringe driver over 1 minute</description>
    <arm_group_label>4: Midazolam 0.075 mg/kg</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients, aged 18 to 65 years inclusive, scheduled to undergo
             diagnostic upper GI endoscopy.

          -  American Society of Anesthesiologists Physical Status (ASA PS) Score I or II.

          -  Weight range 60 to 120 kg inclusive.

          -  Body mass index (BMI) 18 to &lt; 30 kg/m2.

          -  Patients with no clinically significant abnormalities in 12 lead ECG recorded at
             Screening.

          -  Female with a negative serum human chorionic gonadotropin (hCG) pregnancy test result
             at Screening and negative urine hCG pregnancy test result on Day 1 before the
             endoscopy procedure.

          -  Patients with negative drugs of abuse serum result at Screening and negative drugs of
             abuse urine result on Day 1 before the endoscopy procedure.

          -  Patient has a negative serum ethanol test result at Screening and a negative ethanol
             saliva test result on Day 1 before the endoscopy procedure.

          -  Patient voluntarily signs and dates an informed consent form (ICF) that is approved by
             an investigational review board (IRB) prior to the conduct of any study procedure.

          -  Patient is willing and able to comply with study requirements and return for a Follow
             up Visit (Visit 3 ± 1 day) after the endoscopy procedure.

        Exclusion Criteria:

          -  Patients with a suspected upper GI bleed an conditions predisposing to hemorrhage at
             the discretion of the investigator.

          -  Has a known sensitivity to benzodiazepines, flumazenil, or anesthetic agents, or a
             medical condition such that these agents are contraindicated.

          -  Patients with evidence of uncontrolled renal, hepatic, central nervous system,
             respiratory, cardiovascular, or metabolic dysfunction, in the opinion of the
             investigator or medical monitor.

          -  Patients taking an agent that inhibits cytochrome P450 subtype 3A4 (CYP3A4) or
             patients who have taken such an agent within 14 days prior to study start or within
             the duration of 7 half lives of the drug, whichever is longer.

          -  Patients in receipt of any investigational drug within 30 days or less than 7 half
             lives (whichever is longer) before the start of the study, or scheduled to receive one
             during the study period.

          -  Chronic use of benzodiazepines for any indication (eg, insomnia, anxiety, spasticity).

          -  Has known or suspected history of alcoholism or drug abuse or misuse within 2 years of
             Screening or evidence of tolerance or physical dependence before dosing with study
             drug.

          -  Patients with clinically significant findings at Screening that, in the investigator's
             opinion, should exclude them from the study.

          -  Patients with a history of laboratory results that show the presence of hepatitis B
             surface antigen (HBs Ag), hepatitis C antibody (HCV Ab), or human immunodeficiency
             virus (HIV).

          -  Patients with an inability to communicate well in English with the investigator.

          -  Lactating female patients.

          -  Patients in whom management of airway is judged to be difficult due to:

               -  obesity (weight &gt; 120 kg, or BMI ≥ 30 kg/m2),

               -  thyro mental distance ≤ 4 cm (&quot;short neck&quot;), or

               -  Mallampati score of 4 (Appendix IV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Helen Keller Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPE Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Borkett KM, Riff DS, Schwartz HI, Winkle PJ, Pambianco DJ, Lees JP, Wilhelm-Ogunbiyi K. A Phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Anesth Analg. 2015 Apr;120(4):771-80. doi: 10.1213/ANE.0000000000000548.</citation>
    <PMID>25502841</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>March 25, 2009</study_first_submitted>
  <study_first_submitted_qc>March 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2009</study_first_posted>
  <results_first_submitted>December 14, 2018</results_first_submitted>
  <results_first_submitted_qc>December 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2019</results_first_posted>
  <disposition_first_submitted>September 8, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 8, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 9, 2010</disposition_first_posted>
  <last_update_submitted>December 14, 2018</last_update_submitted>
  <last_update_submitted_qc>December 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CNS 7056</keyword>
  <keyword>Procedural Sedation</keyword>
  <keyword>Sedation</keyword>
  <keyword>Endoscopy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1: CNS 7056 0.10 mg/kg</title>
          <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
        </group>
        <group group_id="P2">
          <title>2: CNS 7056 0.15 mg/kg</title>
          <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
        </group>
        <group group_id="P3">
          <title>3: CNS 7056 0.20 mg/kg</title>
          <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
        </group>
        <group group_id="P4">
          <title>4: Midazolam 0.075 mg/kg</title>
          <description>Midazolam: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1: CNS 7056 0.10 mg/kg</title>
          <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
        </group>
        <group group_id="B2">
          <title>2: CNS 7056 0.15 mg/kg</title>
          <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
        </group>
        <group group_id="B3">
          <title>3: CNS 7056 0.20 mg/kg</title>
          <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
        </group>
        <group group_id="B4">
          <title>4: Midazolam 0.075 mg/kg</title>
          <description>Midazolam: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.7" spread="13.33"/>
                    <measurement group_id="B2" value="38.8" spread="14.08"/>
                    <measurement group_id="B3" value="43.2" spread="13.95"/>
                    <measurement group_id="B4" value="44.6" spread="13.64"/>
                    <measurement group_id="B5" value="41.1" spread="13.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169.33" spread="9.603"/>
                    <measurement group_id="B2" value="168.42" spread="10.283"/>
                    <measurement group_id="B3" value="168.97" spread="7.432"/>
                    <measurement group_id="B4" value="171.55" spread="9.650"/>
                    <measurement group_id="B5" value="169.57" spread="9.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.22" spread="10.583"/>
                    <measurement group_id="B2" value="75.17" spread="10.869"/>
                    <measurement group_id="B3" value="75.13" spread="11.027"/>
                    <measurement group_id="B4" value="75.45" spread="10.099"/>
                    <measurement group_id="B5" value="74.74" spread="10.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.47" spread="2.091"/>
                    <measurement group_id="B2" value="26.43" spread="2.158"/>
                    <measurement group_id="B3" value="26.24" spread="2.725"/>
                    <measurement group_id="B4" value="25.59" spread="2.262"/>
                    <measurement group_id="B5" value="25.93" spread="2.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Success Rates of the Procedure</title>
        <description>Success of the procedure is a composite endpoint consisting of: MOAA/S scores ≤4 on three consecutive measurements after administration of study drug AND completion of the endoscopy procedure AND no requirement for rescue sedative medication AND no requirement for manual or mechanical ventilation</description>
        <time_frame>From start of study drug injection to patient discharge</time_frame>
        <population>All randomized patients who received a dose of study drug, underwent the endoscopy procedure, and had at least 1 efficacy assessment (Intent-to-treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>1: CNS 7056 0.10 mg/kg</title>
            <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
          </group>
          <group group_id="O2">
            <title>2: CNS 7056 0.15 mg/kg</title>
            <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
          </group>
          <group group_id="O3">
            <title>3: CNS 7056 0.20 mg/kg</title>
            <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
          </group>
          <group group_id="O4">
            <title>4: Midazolam 0.075 mg/kg</title>
            <description>Midazolam: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rates of the Procedure</title>
          <description>Success of the procedure is a composite endpoint consisting of: MOAA/S scores ≤4 on three consecutive measurements after administration of study drug AND completion of the endoscopy procedure AND no requirement for rescue sedative medication AND no requirement for manual or mechanical ventilation</description>
          <population>All randomized patients who received a dose of study drug, underwent the endoscopy procedure, and had at least 1 efficacy assessment (Intent-to-treat population)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Fully Alert</title>
        <description>Time to first of 3 consecutive Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scores of 5 following study drug administration in patients who underwent the endoscopy procedure</description>
        <time_frame>From study drug administration until fully alert criteria are reached</time_frame>
        <population>All randomized patients who received a dose of study drug, underwent the endoscopy procedure, and had at least 1 efficacy assessment (Intent-to-treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>1: CNS 7056 0.10 mg/kg</title>
            <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
          </group>
          <group group_id="O2">
            <title>2: CNS 7056 0.15 mg/kg</title>
            <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
          </group>
          <group group_id="O3">
            <title>3: CNS 7056 0.20 mg/kg</title>
            <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
          </group>
          <group group_id="O4">
            <title>4: Midazolam 0.075 mg/kg</title>
            <description>Midazolam: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Fully Alert</title>
          <description>Time to first of 3 consecutive Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scores of 5 following study drug administration in patients who underwent the endoscopy procedure</description>
          <population>All randomized patients who received a dose of study drug, underwent the endoscopy procedure, and had at least 1 efficacy assessment (Intent-to-treat population)</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="10.04"/>
                    <measurement group_id="O2" value="13.4" spread="6.51"/>
                    <measurement group_id="O3" value="12.1" spread="5.26"/>
                    <measurement group_id="O4" value="17.2" spread="16.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Ready for Discharge</title>
        <description>Time to first of 3 consecutive Aldrete scores ≥9 after the end endoscopy procedure</description>
        <time_frame>From the end of the endoscopy procedure up to 120 minutes or until 3 consecutive Aldrete scores of ≥9 are reached, whichever occurs first</time_frame>
        <population>All randomized patients who received a dose of study drug, underwent the endoscopy procedure, and had at least 1 efficacy assessment (Intent-to-treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>1: CNS 7056 0.10 mg/kg</title>
            <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
          </group>
          <group group_id="O2">
            <title>2: CNS 7056 0.15 mg/kg</title>
            <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
          </group>
          <group group_id="O3">
            <title>3: CNS 7056 0.20 mg/kg</title>
            <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
          </group>
          <group group_id="O4">
            <title>4: Midazolam 0.075 mg/kg</title>
            <description>Midazolam: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Ready for Discharge</title>
          <description>Time to first of 3 consecutive Aldrete scores ≥9 after the end endoscopy procedure</description>
          <population>All randomized patients who received a dose of study drug, underwent the endoscopy procedure, and had at least 1 efficacy assessment (Intent-to-treat population)</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="9.96"/>
                    <measurement group_id="O2" value="12.8" spread="5.96"/>
                    <measurement group_id="O3" value="11.8" spread="4.96"/>
                    <measurement group_id="O4" value="17.2" spread="12.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events (TEAEs) were collected from Time 0 on Day 1 to the Follow-up Visit on Day 4, and were followed until resolution (with or without sequelae) up to a maximum of 30 days after Time 0.</time_frame>
      <desc>Total number of participants affected with Other (Not Including Serious) Adverse Events represents overall number of participants with non-serious TEAEs reported with a threshold of 5% in any of the arms</desc>
      <group_list>
        <group group_id="E1">
          <title>1: CNS 7056 0.10 mg/kg</title>
          <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
        </group>
        <group group_id="E2">
          <title>2: CNS 7056 0.15 mg/kg</title>
          <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
        </group>
        <group group_id="E3">
          <title>3: CNS 7056 0.20 mg/kg</title>
          <description>CNS 7056: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
        </group>
        <group group_id="E4">
          <title>4: Midazolam 0.075 mg/kg</title>
          <description>Midazolam: Administered as a single intravenous injection by a syringe driver over 1 minute</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngeolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At least 60 days prior to submission for publication, presentation or use, sponsor shall review and comment any proposed oral or written publication, which period may be extended for an additional 30 days. To seek patent protection, sponsor shall have the right to delay the proposed publication for an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Information</name_or_title>
      <organization>PAION UK Ltd</organization>
      <email>reg_paion@paion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

